def research_innovative_cancer_treatments(cancer_type, aggressiveness='high', current_standard_of_care=None):
    """
    Systematic framework for researching innovative treatments for aggressive cancers.
    
    Args:
        cancer_type: Type of cancer (e.g., 'glioblastoma multiforme')
        aggressiveness: Tumor aggressiveness level
        current_standard_of_care: Current standard treatment approach
    
    Returns:
        Structured research findings across 5 domains with confidence ratings
    """
    
    domains = {
        'immunotherapy': {
            'sub_approaches': ['CAR-T cell therapy', 'dendritic cell vaccines', 
                              'checkpoint inhibitors', 'bispecific antibodies'],
            'key_metrics': ['overall_survival', 'progression_free_survival', 
                           'objective_response_rate', 'clinical_trial_phase'],
            'timing_insight': 'Neoadjuvant/perioperative immunotherapy timing shows superior outcomes'
        },
        'oncolytic_biological': {
            'sub_approaches': ['oncolytic viruses (HSV, adenovirus, poliovirus)', 
                              'bacteriotherapy', 'gene therapy vectors'],
            'key_metrics': ['viral_replication_efficacy', 'immune_activation', 
                           'survival_outcomes', 'FDA/regulatory_status'],
            'delivery_insight': 'Local/intratumoral delivery critical for BBB-protected tumors'
        },
        'drug_delivery': {
            'sub_approaches': ['nanoparticles', 'convection-enhanced delivery',
                              'BBB disruption (focused ultrasound)', 'local implants'],
            'key_metrics': ['BBB_penetration_rate', 'drug_concentration_achieved',
                           'toxicity_profile', 'delivery_precision'],
            'key_pattern': 'Local delivery consistently outperforms systemic for CNS tumors'
        },
        'targeted_molecular': {
            'sub_approaches': ['EGFR/EGFRvIII inhibitors', 'IDH mutation targeting',
                              'BRAF alterations', 'metabolic vulnerabilities',
                              'signaling pathway inhibitors'],
            'key_metrics': ['molecular_response_rate', 'biomarker_stratification',
                           'resistance_mechanisms', 'combination_potential'],
            'challenge': 'Tumor heterogeneity limits single-target approaches'
        },
        'microenvironment_combination': {
            'sub_approaches': ['TME modulation', 'synthetic lethality',
                              'radiosensitizers', 'multi-modal combinations'],
            'key_metrics': ['synergy_evidence', 'immune_microenvironment_change',
                           'combination_safety', 'survival_benefit_vs_standard'],
            'key_pattern': 'Single-modality approaches show limited efficacy; combinations essential'
        }
    }
    
    meta_patterns = {
        'delivery': 'Local/regional delivery outperforms systemic for BBB-protected tumors',
        'timing': 'Neoadjuvant perioperative immunotherapy timing shows superior outcomes',
        'combination': 'Multi-modal approaches essential due to tumor heterogeneity and adaptive resistance',
        'biomarkers': 'Patient stratification by molecular biomarkers improves response rates',
        'emerging': 'mRNA vaccines, bispecific antibodies, and CRISPR-based approaches represent next frontier'
    }
    
    return {
        'cancer_type': cancer_type,
        'research_domains': domains,
        'meta_patterns': meta_patterns,
        'recommended_approach': 'Prioritize local delivery + combination strategies + neoadjuvant timing'
    }